CLRB
NASDAQCellectar Biosciences Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Website
News25/Ratings2
News · 26 weeks17-50%
2025-10-262026-04-19
Mix890d
- Other3(38%)
- Earnings2(25%)
- SEC Filings2(25%)
- Analyst1(13%)
Latest news
25 items- PRCellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026FLORHAM PARK, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the acceptance of an abstract for poster presentation at the American Society of Clinical Oncology Annual Meeting taking place May 29 - June 2 in Chicago, Illinois. "We are pleased to share data from this important subset of r/r WM patients for whom there are no approved therapies and remaining options are restricted to salvage therapies which provide limited benefit. It is important to note that approximately 60% of drugs used for all WM patients are
- PRCellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)FLORHAM PARK, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the first patient has been enrolled in the Phase 1b trial of CLR 121125 (CLR 125) for the potential treatment of triple negative breast cancer (TNBC). CLR 125 is Cellectar's proprietary Auger-emitting radioconjugate incorporating iodine-125 to achieve intracellular delivery and direct DNA-level damage in tumor cells. The molecular structure of CLR 125 is identical to that of iopofosine I 131 (CLR 131) and the demonstrated clinical activity, safety
- ANALYSTCellectar Biosciences upgraded by Maxim Group with a new price targetMaxim Group upgraded Cellectar Biosciences from Hold to Buy and set a new price target of $10.00
- SECCellectar Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Cellectar Biosciences, Inc. (0001279704) (Filer)
- SECSEC Form 10-K filed by Cellectar Biosciences Inc.10-K - Cellectar Biosciences, Inc. (0001279704) (Filer)
- PRCellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate UpdatesOn track to submit Conditional Marketing Authorization for iopofosine I 131 to European Medicines Agency in Q3 2026 for potential 2027 EU commercialization as a treatment for Waldenström Macroglobulinemia Initiated Phase 1b dose finding study for CLR 125 in Triple Negative Breast Cancer with early data expected by mid-year 2026 Company to Hold Webcast and Conference Call at 8:30 AM ET Today FLORHAM PARK, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced financial results for the year ended December 31
- PRCellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026FLORHAM PARK, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the Company will report financial results for the full year ended December 31, 2025, and provide a corporate update on March 4, 2026, at 8:30 a.m. Eastern Time. Conference Call & Webcast Details:Date:Wednesday, March 4, 2026Time:8:30 am Eastern TimeToll Free:1-800-717-1738Conference ID:Webcast:08197Click HERE A replay of the corporate presentation will be available on the Events section of the Company's Investor Relations website. About Cellectar B
- PRCellectar Biosciences Expands Global Intellectual Property EstateStrengthens Protection Around Broad Portfolio of Cancer-Targeting Drug Conjugates and Enabling Technologies Provides Key Coverage Across Europe Ahead of Planned 3Q26 Filing for Conditional Marketing Approval with the European Medicines Agency (EMA) for Iopofosine I 131 as a Treatment for Waldenström Macroglobulinemia FLORHAM PARK, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced a broad expansion of its global intellectual property (IP) estate, including newly issued patents across Europe, Asia-Pacific, the Middle
- PRCellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare ConferenceFollowing Guidance from the European Medicines Agency's (EMA) Scientific Advice Working Party (SAWP) Regarding Iopofosine I 131 for the Treatment of Waldenstrom's Macroglobulinemia (WM), Expects to Submit for Conditional Marketing Approval in Europe in 3Q 2026 Plans to Present Final Results and Subset Analysis of WM Patients from the Phase 2 CLOVER WaM Clinical Study of Iopofosine I 131 Anticipates Dosing of First Patients in Phase 1b Study of CLR 125 for the Treatment of Triple Negative Breast Cancer in 1Q26 with Interim Data Mid-2026 FLORHAM PARK, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused
- INSIDERDirector Neis John sold $732 worth of shares (198 units at $3.70) (SEC Form 4)4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)
- PRCellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha TherapiesFLORHAM PARK, N.J. and LANSING, Mich., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced a multi-year supply agreement with Ionetix Corporation, a leading cyclotron technology innovator and full-service radioisotope manufacturer, for two critical alpha-emitting radioisotopes: Actinium-225 (Ac-225) and Astatine-211 (At-211). Under the agreement, Ionetix will provide Cellectar with a reliable, clinical and commercial-scale supply of cGMP-grade Ac-225 and At-211 to support its drug development programs through clinical trial
- SECSEC Form 424B3 filed by Cellectar Biosciences Inc.424B3 - Cellectar Biosciences, Inc. (0001279704) (Filer)
- SECCellectar Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Cellectar Biosciences, Inc. (0001279704) (Filer)
- PRCellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateExpects to Submit Conditional Marketing Approval Application in Europe for Iopofosine I 131 in Refractory (post-BTKi) Waldenstrom's Macroglobulinemia in 2026 Following Advice and Guidance from Scientific Advice Working Party (SAWP) Initiated Phase 1b Study of CLR 125 for TNBC Received Rare Pediatric Drug Designation for Iopofosine I 131 in Inoperable Relapsed/Refractory Pediatric High-Grade Glioma (r/r pHGG) Company to Hold Webcast and Conference Call at 8:30 AM ET Today FLORHAM PARK, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of ca
- SECSEC Form 10-Q filed by Cellectar Biosciences Inc.10-Q - Cellectar Biosciences, Inc. (0001279704) (Filer)
- PRCellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025FLORHAM PARK, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the company will report financial results for the third quarter ended September 30, 2025, and provide a corporate update on November 13, 2025, at 8:30 a.m. Eastern Time. Conference Call & Webcast Details:Date:Thursday, November 13, 2025Time:8:30 am Eastern TimeToll Free:1-800-717-1738Conference ID:42734Webcast:Click HERE A replay of the corporate presentation will be available on the Events section of the company's Investor Relations website. Abo
- PRCellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade GliomaFLORHAM PARK, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the U.S. Food and Drug Administration (FDA) has granted rare pediatric drug designation (RPDD) for iopofosine I 131 in inoperable relapsed or refractory pediatric high-grade glioma (r/r pHGG). Iopofosine I 131 is a potential first-in-class, novel cancer targeting agent utilizing a phospholipid ether as a radioconjugate monotherapy. The FDA previously granted Orphan Drug Designation for iopofosine I 131 for the treatment of pHGG. "Receiving Rare Pediatr
- SECSEC Form S-1 filed by Cellectar Biosciences Inc.S-1 - Cellectar Biosciences, Inc. (0001279704) (Filer)
- PRCellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer ResearchFLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that Jarrod Longcor, chief operating officer of Cellectar, presented positive preclinical data in a poster at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research that took place from September 28 through October 1, 2025, in Boston, Massachusetts. The poster highlighted preclinical data from CLR 121225 (CLR 225), the Company's novel actinium-based radio conjugate alpha-emitter for treatment in pancreatic du
- SECCellectar Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Other Events, Financial Statements and Exhibits8-K - Cellectar Biosciences, Inc. (0001279704) (Filer)
- PRCellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 MillionFLORHAM PARK, N.J., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB) ("Cellectar" or the "company"), a late-stage biotechnology company focused on the discovery and development of drugs for the treatment of cancer, today announced an agreement between the company and several institutional investors to exercise certain existing warrants (the "Existing Warrants") for gross proceeds to the company of approximately $5.8 million prior to deducting placement agent fees and estimated offering expenses. Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for this transaction. The Existing Warrants were issued by the company on October 25, 2022, July 21
- SECCellectar Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Cellectar Biosciences, Inc. (0001279704) (Filer)
- PRCellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM)Following Scientific Advice and Guidance from Scientific Advice Working Party (SAWP) of EMA, Submission of CMA Application for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) WM Expected in Early 2026 Potential 2027 European Approval and Commercial Launch of Iopofosine I 131 as a Treatment for Refractory (post-BTKi) WM FLORHAM PARK, N.J., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that after a scientific advice procedure, the Scientific Advice Working Party (SAWP) of the European Medicines Agency (
- PRCellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric CancerFLORHAM PARK, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that Jarrod Longcor, chief operating officer of Cellectar, delivered an oral presentation followed by a 55-minute panel discussion with other experts in the field at the American Association for Cancer Research (AACR) Special Conference on Pediatric Cancer that took place September 25-28 in Boston, Massachusetts. The oral presentation highlighted interim data from the Phase 1b dose and regimen optimization study of iopofosine I 131 in inoperable relapse
- PRCellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC)FLORHAM PARK, N.J. and LONDON and CHARLOTTESVILLE, Va., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. ("Cellectar") (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, and Evestia Clinical ("Evestia"), a leading independent global specialist Contract Research Organization (CRO), have entered into an agreement whereby Evestia will provide Cellectar with full CRO services for their upcoming Phase 1b study evaluating CLR 125 for the treatment of triple-negative breast cancer (TNBC). CLR 125 is an iodine-125 Auger-emitting drug candidate targeting solid tumors, such as triple negative bre